Reducing Variability in Cytokine Activity Reporting

Ensuring the quality and consistency of ancillary materials used in the manufacture of cell and gene therapies is critical to both controlling costs and ensuring the integrity of the therapeutic product. It is our responsibility as ancillary material manufacturers to reduce the variability that biomanufacturing presents. This is especially important when considering the manufacture of